Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Bulsara

Showing results (191-200 of 199) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 199 results.
Lancet (London, England)|June 24, 2010
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trialJayant S Vaidya, David J Joseph, Jeffrey S Tobias, et al.
Lancet (London, England)|November 15, 2013
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trialJayant S Vaidya, Frederik Wenz, Max Bulsara, et al.
Gynecologic Oncology|February 24, 2020
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]Paul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|May 24, 2019
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 8, 2021
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448Paul A Cohen, Aime Powell, Steffen Böhm, et al.
BMJ (Clinical Research Ed.)|August 21, 2020
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trialJayant S Vaidya, Max Bulsara, Michael Baum, et al.
Clinical and Experimental Rheumatology|February 28, 2025
Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating ScaleUmesh A Badrising, Robert Henderson, Stephen Reddel, et al.
JAMA Oncology|April 3, 2020
Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast CancerJayant S Vaidya, Max Bulsara, Christobel Saunders, et al.
British Journal of Cancer|May 26, 2021
New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancerJayant S Vaidya, Max Bulsara, Michael Baum, et al.
Pageof 20

Showing results (191-200 of 199) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 199 results.
Lancet (London, England)|June 24, 2010
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trialJayant S Vaidya, David J Joseph, Jeffrey S Tobias, et al.
Lancet (London, England)|November 15, 2013
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trialJayant S Vaidya, Frederik Wenz, Max Bulsara, et al.
Gynecologic Oncology|February 24, 2020
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]Paul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|May 24, 2019
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 8, 2021
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448Paul A Cohen, Aime Powell, Steffen Böhm, et al.
BMJ (Clinical Research Ed.)|August 21, 2020
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trialJayant S Vaidya, Max Bulsara, Michael Baum, et al.
Clinical and Experimental Rheumatology|February 28, 2025
Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating ScaleUmesh A Badrising, Robert Henderson, Stephen Reddel, et al.
JAMA Oncology|April 3, 2020
Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast CancerJayant S Vaidya, Max Bulsara, Christobel Saunders, et al.
British Journal of Cancer|May 26, 2021
New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancerJayant S Vaidya, Max Bulsara, Michael Baum, et al.
Pageof 20